Invivyd Stock Today
| IVVD Stock | USD 2.55 0.05 2.00% |
PerformanceFair
| Odds Of DistressAverage
|
Invivyd is trading at 2.55 as of the 6th of January 2026, a 2.00% up since the beginning of the trading day. The stock's lowest day price was 2.37. Invivyd has over 55 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 7th of December 2025 and ending today, the 6th of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of August 2021 | Category Healthcare | Classification Health Care |
Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Invivyd, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts. The company has 277.06 M outstanding shares of which 28.63 M shares are currently shorted by private and institutional investors with about 4.95 trading days to cover. More on Invivyd
Moving together with Invivyd Stock
Moving against Invivyd Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Invivyd Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| VP CEO | Heidi MS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsInvivyd can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Invivyd's financial leverage. It provides some insight into what part of Invivyd's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Invivyd (IVVD) is traded on NASDAQ Exchange in USA and employs 99 people. Invivyd is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 692.66 M. Invivyd conducts business under Biotechnology sector and is part of Health Care industry. The entity has 277.06 M outstanding shares of which 28.63 M shares are currently shorted by private and institutional investors with about 4.95 trading days to cover.
Invivyd currently holds about 418.67 M in cash with (170.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Invivyd Probability Of Bankruptcy
Ownership AllocationInvivyd has a total of 277.06 Million outstanding shares. The majority of Invivyd outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Invivyd to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Invivyd. Please pay attention to any change in the institutional holdings of Invivyd as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Invivyd Ownership Details
Invivyd Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2025-06-30 | 637 K | |
| Deutsche Bank Ag | 2025-06-30 | 585.4 K | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 513.4 K | |
| Gsa Capital Partners Llp | 2025-06-30 | 435.3 K | |
| Aqr Capital Management Llc | 2025-06-30 | 423.5 K | |
| Tang Capital Management Llc | 2025-06-30 | 400 K | |
| Goldman Sachs Group Inc | 2025-06-30 | 387.9 K | |
| Cubist Systematic Strategies, Llc | 2025-06-30 | 326.8 K | |
| State Street Corp | 2025-06-30 | 272.9 K | |
| Mithril Ii Gp Lp | 2025-06-30 | 11.2 M | |
| Maverick Capital Ltd | 2025-06-30 | 10.2 M |
Invivyd Historical Income Statement
Invivyd Stock Against Markets
Invivyd Corporate Management
| Laura Walker | CoFounder Officer | Profile | |
| Elham PharmD | Chief Officer | Profile | |
| Peter MD | Chief Officer | Profile | |
| Robert Allen | Chief Officer | Profile | |
| Jill JD | Chief Secretary | Profile | |
| Mark Wingertzahn | Senior Affairs | Profile | |
| Timothy Lee | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Invivyd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. For information on how to trade Invivyd Stock refer to our How to Trade Invivyd Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Invivyd. If investors know Invivyd will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Invivyd listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Revenue Per Share | Quarterly Revenue Growth 0.412 | Return On Assets | Return On Equity |
The market value of Invivyd is measured differently than its book value, which is the value of Invivyd that is recorded on the company's balance sheet. Investors also form their own opinion of Invivyd's value that differs from its market value or its book value, called intrinsic value, which is Invivyd's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Invivyd's market value can be influenced by many factors that don't directly affect Invivyd's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Invivyd's value and its price as these two are different measures arrived at by different means. Investors typically determine if Invivyd is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Invivyd's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.